Search Results

Phenomix Sciences has secured $5.5 million in Series A funding from new investors, DexCom, Inc. and Labcorp, and existing investors, including Health2047.

Phenomix Sciences, a precision medicine biotechnology company that brings data intelligence to the treatment of obesity, announces the launch of a new MyPhenomeTM test that now allows patients to test for all three identified phenotypes - Emotional Hunger, Hungry Gut and Hungry Brain - in one simple test.

Phenomix Sciences (Phenomix), a precision medicine biotechnology company that brings data-driven precision medicine to obesity treatment, announced today the United States Patent and Trademark Office (USPTO) has issued the first patent related to its obesity phenotyping technology.

Phenomix Sciences announces the launch of a second of its gut-brain axis phenotyping test, MyPhenome Hungry Brain.

Results from a new obesity study conducted at Mayo Clinic to assess the utility of the Phenomix Sciences MyPhenome Hungry Brain test were presented at ObesityWeek 2023 by Mayo Clinic’s Dr. Diego Anazco, M.D., research postdoctoral fellow in the lab of Dr. Andres Acosta, M.D., Ph.D.

Phenomix Sciences, a precision medicine biotechnology company that brings data intelligence to the treatment of obesity, announces the results of a groundbreaking independent study led by Mayo Clinic and presented at Digestive Disease Week 2024.

Phenomix Sciences, a precision obesity biotechnology company, announces the launch of its biobanking registry and outcomes study.

Biomedical startup company Phenomix Sciences (Phenomix) has signed an exclusive technology licensing agreement with Mayo Clinic for a novel blood test that accurately predicts obesity phenotypes. The multi-level “omics” MyPhenome™ test leverages technology developed at Mayo Clinic to analyze genomics, metabolomics and hormone levels.

Atrion Corporation (NASDAQ: ATRI), a developer and manufacturer of products primarily for medical applications, today announced that it has entered into an agreement and plan of merger with Nordson Corporation pursuant to which Nordson will acquire Atrion for $460 per share in cash, representing a total equity value of approximately $815 million.